External validation of hemoglobin and neutrophil levels as predictors of the effectiveness of ipilimumab plus nivolumab for treating renal cell carcinoma
In this large cohort, we validated our earlier observation that hemoglobin and neutrophil levels can be reliable predictors of the effectiveness of IPI + NIVO in advanced RCC. Thus, our approach may aid in selecting the optimal first-line therapy for RCC.
Authors
- Kazumi Taguchi (ORCID: https://orcid.org/0000-0002-3092-5114)
- Junya Furukawa (ORCID: https://orcid.org/0000-0001-8974-9218)
- Makito Miyake (ORCID: https://orcid.org/0000-0001-9503-7356)
- Takahiro Yasui (ORCID: https://orcid.org/0000-0003-2197-2477)
- Ryotaro Tomida (ORCID: https://orcid.org/0000-0002-2518-0197)
- Kazutoshi Fujita (ORCID: https://orcid.org/0000-0002-6774-7497)
- Yoshihiko Tasaki (ORCID: https://orcid.org/0000-0002-1830-7452)
- Yosuke Sugiyama (ORCID: https://orcid.org/0000-0001-8436-5872)
- Hideki Iwamoto (ORCID: https://orcid.org/0000-0001-5688-1335)
- Shimpei Yamashita (ORCID: https://orcid.org/0000-0001-7402-6164)
- Shuzo Hamamoto (ORCID: https://orcid.org/0000-0002-9087-4152)
- Noriyuki Ito
Institutions
- Wakayama Medical University (JP)
- Nagoya City University (JP)
- Japanese Red Cross Society Wakayama Medical Center (JP)
- Tottori University (JP)
- Nara Medical University (JP)
- Kobe University (JP)
- Kindai University (JP)
- Tokushima University (JP)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2024-09-02
- DOI
- https://doi.org/10.3389/fonc.2024.1400041
- Citations
- 1
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.42